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Flos carthami is a traditional Chinese herbal medicine. Clinically, the Flos carthami Injection has been used concomitantly with
other Western drugs and may be used concomitantly with β-blockers, such as metoprolol, to treat cerebrovascular and coronary
heart diseases, in China. Metoprololis a CYP2D6substrateand is predominantly metabolized by this isozyme. However, we do not
know whether there is an eﬀect of Flos carthami on CYP2D6 and the consequences of such an eﬀect. Concern is raised regarding
the possible herb-drug interaction. In this report, the eﬀects of Flos carthami on the activity of CYP2D6 in vivo and in vitro and on
the pharmacokinetics of metoprolol, in rats, are investigated. To assess the inhibitory potency of Flos carthami, the concentration
associated with 50% inhibition (IC50) of dextromethorphan metabolism was determined based on the concentration-inhibition
curves. The inhibitory eﬀect of Flos carthami on CYP2D6 was also compared with cimetidine in vitro. Flos carthami could
signiﬁcantly inhibit CYP2D6 in rats both in vitro and in vivo (P<. 05) and could slow down the metabolic rate of metoprolol
as suggested by prolonged t1/2 (67.45%), by increased Cmax (74.51%) and AUC0−∞ (76.89%). These results suggest that CYP2D6 is
a risk factor when Flos carthami is administered concomitantly with metoprolol or other CYP2D6 substrates.
1.Introduction
Traditional herbal medications have been used concomi-
tantly with Western drugs to treat a variety of diseases in
China and other countries [1–4]. One of the concerns of
healthcare professionals is that there is a lack of knowledge
with regard to the pharmacokinetics of herbs, and there is
a high possibility of herb-drug interaction [5]. This herb-
drug interaction may signiﬁcantly alter the eﬃcacy and
safety of the medications and result in therapeutic failure
or toxicity [6–9]. Unfortunately, the availability of such
information is very limited. It is well known that cytochrome
P450 (CYP450) enzymes play a major role in drug-drug
interactions. CYP2D6 isoform is one of the important
members of the CYP450 family and mediates metabolism
in almost 25% of the CYP450-metabolized drugs [10]. To
date, CYP2D6-mediated drug-drug interactions have been
extensively investigated [11]. However, there are only a
few published CYP2D6-mediated studies with regard to the
herb-drug interactions [12–15].
Flos carthami Injection is prepared from Flos carthami,a
traditionalChineseherbalmedicine.Clinically,Floscarthami
Injection has been used in combination with β-blockers,
such as metoprolol, to treat cerebrovascular and coronary
heart diseases in China. Metoprolol is a CYP2D6 substrate
and is predominantly metabolized by this isozyme. However,
we do not know whether there is an eﬀect of Flos carthami
on CYP2D6 and the consequences of such an eﬀect on
its substrates. To this end, we have investigated the eﬀects
of Flos carthami on CYP2D6 and on the pharmacokinetics
of metoprolol in rats. Our results show that Flos carthami
exhibits an inhibitory eﬀect on CYP2D6 and could slow
down the metabolic rate of metoprolol.
2. Methods
2.1. Chemicals and Reagents. Flos carthami Injection (each
milliliter injection contained 0.5g Flos carthami)w a s
purchased from Shanxi Yabao Pharmaceuticals Company
(Shanxi, China). Dextromethorphan, dextrophan, β-glu-
curonidase, isocitric dehydrogenase, and DL-isocitric acid
trisodium were obtained from Sigma Chemical Co. (St.
Louis, Mo, USA). NADPNa2 was purchased from Geneview2 Evidence-Based Complementary and Alternative Medicine
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Figure 1: HPLC chromatograms of urine of rats in vivo. (a) Blank group, (b) Flos carthami-treated group. DX: dextrophan (metabolite of
dextromethorphan); DB: buprenorphine (internal standard); DM: dextromethorphan.
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Figure 2: HPLC chromatograms of liver microsome of rats in vitro. (a) Blank group and (b) Flos carthami-treated group. DX: dextrophan
(metabolite of dextromethorphan); DB: buprenorphine (internal standard); DM: dextromethorphan.
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Figure 3:Linearregressionofexperimentaldatainvivoandinvitro.
(Texas, USA). Metoprolol tartrate tablets were purchased
from AstraZeneca Pharmaceuticals Company (Jiangsu,
China). Metoprolol tartrate standard, bisoprolol fumarate
standard, and buprenorphine standard were obtained from
the National Institute for the Control of Pharmaceutical and
Biological Products (Beijing, China). All other reagents were
of analytical or HPLC grade.
2.2. Animals and Treatments. Wistar rats (180 ± 20g, male)
were supplied by the Animal Experimental Center of the
Harbin Medical University, which was fully accredited by
the Institutional Animal Care and Use Committee (IACUC)
and handled in a manner that met all the recommendations
formulated by the National Society for Medical Research and
Guidelines for the Care and Use of Laboratory Animals. The
rats were randomly divided into two groups (Flos carthami-
treated and blank control) with eight rats in each group.
Treated and control groups were administered a 1.8mL/kg
Flos carthami Injection and physiological saline by caudal
vein for seven days, respectively. On day eight, the animals
in both groups were given dextromethorphan (6mg/kg)
orally. Eight hours later, the rats were anesthetized with 4%
halothane, and the chest was opened for removal of the liver.Evidence-Based Complementary and Alternative Medicine 3
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Figure 4: The inhibition curve of Flos carthami on dextromethor-
phan metabolic rate (mean ± SD, n = 8). The concentration of Flos
carthami was ranging from 0, 5, 10, 15, 20, 25, 30, to 45mg/mL,
respectively.
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Figure 5: Comparison of the inhibitory activities of Flos carthami
with cimetidine (mean ± SD; n = 8): (a) Blank group. (b) Flos
carthami-treated group. (c) Cimetidine-treated group. ∗P<. 05
versus blank group.
(the rats were fasted for 24h before being killed.) The urine
a n dl i v e ro fe a c hr a tw e r ec o l l e c t e da n ds t o r e da t−20◦Co r
−80◦C for further analysis.
2.3. Sample Treatments and HPLC Conditions. One milliliter
ofurinewith50μLinternalstandardbuprenorphine(2mM)
was mixed with 1mL sodium acetate buﬀer (pH 5.0) and
incubated at 37◦C overnight. After incubation, the urine
was mixed with 1mL NaOH (3M), extracted with 3mL
extraction mixture (n-hexane: n-butanol, 9:1, v/v), and
centrifuged for 5min at 3000×g. Two hundred microliters
of HCl (0.01M) was added to the organic phase, and the
mixture was centrifuged for 5min at 3000×g. The aqueous
phase of 20μL was injected into the Waters HPLC system
2010 (Waters, USA) with a ﬂuorescence detector, at an
excitation wavelength of 280nm and an emission wavelength
of 310nm. Dextromethorphan, dextrophan, and buprenor-
phine were separated on a Hypersil-C6H5 column (4.6mm
× 250mm, 5μm, Elite Co.). The mobile phase, at a ﬂow
rate of 1mL/min, consisted of 0.02M potassium dihydrogen
phosphate,0.02Msodiumhexanesulfonate,acetonitrile,and
methanol (33:33:100:94, v/v/v/v).
2.4. Microsomal Preparation and Incubation Conditions.
Microsomes were prepared by diﬀerential centrifugation
as described previously [16]. The protein content was
quantiﬁed according to the method of Bradford [17]. Liver
m i c r o s o m e sw e r er e s u s p e n d e di na na s s a yb u ﬀer (20mM
DL-isocitric acid trisodium, 1 × 103 U/l isocitric dehydro-
genase, and 1mM MgCl2) and incubated at a ﬁnal protein
concentration of 1mg/mL (500μL ﬁnal volume) for 45min
at37◦C,with0.3mMdextromethorphanand1mMNADP+.
The reactions were terminated by acidiﬁcation with ice
cold 20% trichloroacetic acid. After incubation, 100μLl i v e r
microsomes solution was mixed with 50μL internal standard
buprenorphine (2mM) and 100μL NaOH (3M) extracted
with 2mL extraction mixture (n-hexane: n-butanol, 9:1,
v/v) and centrifuged for 5min at 3000×g. One hundred and
ﬁfteen microliters of HCl (0.01M) were added to the organic
phase,andthemixturewascentrifugedfor5minat3000×g.
The aqueous phase of 20μL was injected into the Waters
HPLC system 2010 for analysis. The HPLC conditions were
the same as described earlier (see Section 2.3).
2.5. Inhibition Curve Study. Dextromethorphan was incu-
bated with Flos carthami Injection at concentrations of 0,
5, 10, 15, 20, 25, 30, and 45mg/mL under the conditions
described earlier, with triplicate incubations for each con-
centration. After incubation and sample treatment, a 20μL
sample was injected into the Waters HPLC system 2010
for analysis. The plot was the logarithm of Flos carthami
Injection concentration (X) versus the inhibition ratio of
Flos carthami on CYP2D6 (Y). To assess the inhibitory
potency of Flos carthami, the concentration associated with
50% inhibition (IC50) of dextromethorphan metabolism was
determined based on the concentration-inhibition curve.
2.6. Comparison of the Inhibitory Activities of Flos carthami
with Cimetidine. The liver microsomes were divided into
three groups: blank group, Flos carthami-treated group
(Flos carthami Injection was added to the blank liver
microsomes; ﬁnal concentration was 30mg/mL), and the
cimetidine-treated group (cimetidine was added to the blank
liver microsomes; ﬁnal concentration was 0.6mg/mL). The
incubation conditions were the same as described earlier (see
Section 2.4), and the metabolic rates of dextromethorphan
were compared.
2.7.EﬀectsofFloscarthamionPharmacokineticsofMetoprolol.
A total of 16 rats were randomized into two groups,
Flos carthami t r e a t e da n db l a n kc o n t r o l .I nFlos carthami
Injection, 1.8mL/kg was administered by the caudal vein
once daily for seven days. One milliliter of physiological
saline was given in the blank control group. On day eight,
metoprolol 25mg/kg was administered by gavage to both
groups. The blood samples for the determination of plasma
concentration of metoprolol were collected by caudal vein at
0 (predose), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, and 9 hours after
the dose of metoprolol and were put into heparinized test
tubes. The plasmas were obtained by centrifugation of the
blood samples and preserved at −20◦C for further analysis.4 Evidence-Based Complementary and Alternative Medicine
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Figure 6: HPLC chromatogram of blood plasma of rats. (a)
Metoprolol standard. (b) Bisoprolol standard.
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Figure 7: Mean plasma concentration-time proﬁles of metoprolol
in control group and Flos carthami-treated group.
Bisoprolol fumarate standard (internal standard) solution
(100μg/mL, 20μL), NaOH solution (2mol/l, 200μL), and
ethyl acetate (2mL) were added to fresh blood plasma
(300μL). Each sample was mixed thoroughly by vortex for
2min and centrifuged for 10min at 3000rpm. Supernatant
of 1.5mL was taken out, and then 2mL ethyl acetate was
addedagaintotherestofthemixture.Eachsamplewasagain
mixed thoroughly by vortex for 2min, and the mixture was
then centrifuged for 10min at 3000rpm, and a supernatant
of 1.5mL was taken out. The two supernatants were mixed,
and sulfuric acid (1%, 100μL) was added to them. They
were then mixed thoroughly by vortex mixing for 2min and
centrifugedfor10minat3000rpm.Theloweraqueousphase
of 20μL was analyzed by HPLC. The HPLC conditions were
Waters HPLC system 2010 (Waters, USA) with ultraviolet
detector,atwavelengthof223nm.Metoprololandbisoprolol
(internalstandard)wereseparatedonaKromasilC18 column
(4.6mm × 250mm, 5μm, Institute of Physical Chemistry
in Dalian, China). The mobile phase, at a ﬂow rate of
0.8mL/min, consisted of methanol, 0.02mol/l potassium
dihydrogenphosphate,and0.01mol/ldipotassiumhydrogen
phosphate (56:22:22, v/v/v).
2.8. Statistical Analysis. The linear regression of experi-
mental data in vivo and in vitro was performed according
to the canonical correlation analysis (CCA). Data were
expressedasmeans ±SDandanalyzedbyDunnett’stest.The
metoprolol pharmacokinetics (PK) parameters were derived
withanonlinearregressioniterativeprogram,DAS1.0(Drug
Clinical Evaluation Center, Anhui, China) pharmacokinetic
statistical software. The derived PK parameters among the
groups were statistically analyzed by ANOVA with Dunnett’s
test. P<. 05 and P<. 01 were considered to be statistically
signiﬁcant and very signiﬁcant, respectively.
3. Results
3.1. In Vivo and In Vitro Study of Dextromethorphan Metab-
olism. Dextromethorphan, dextrophan, and buprenorphine
in the urine and in the rat liver microsomes of blank control
and the Flos carthami-treated groups were analyzed by
HPLC.Thechromatographiesofdextrophan,dextromethor-
phan,andbuprenorphineinvivoandinvitroofblankcontrol
and Flos carthami-treated rats were separated well (Figures
1 and 2). The rate of dextromethorphan metabolism in the
treated group was lower than that in the control group both
in vivo and in vitro (111.23 ± 26.20 in the Flos carthami-
treated group and 160.95 ± 37.23 in the control in vivo;
n = 8, P<. 05; 0.037 ± 0.008 in microsomes prepared
from the Flos carthami-treated rats and 0.068 ± 0.020 in
control rats in vitro; n = 8, P<. 05). The data for dex-
tromethorphan metabolism in vivo and in vitro were further
plotted as X and Y (X: dextrophan/dextromethorphan in
vivo; Y: dextrophan/dextromethorphan in vitro)t or e v e a l
the correlation between the in vivo and in vitro ﬁnd-
ings. The results showed that the rate of dextromethor-
phan metabolism inhibited by Flos carthami correlated
well in vivo and in vitro (r = 0.9389) (Figure 3). All
data suggested that Flos carthami inhibited the activity of
CYP2D6.
3.2.InhibitionCurveandIC50 ofFloscarthami. Theinﬂuence
level of Flos carthami on dextromethorphan metabolism
was investigated in rat liver microsomes prepared from
Flos carthami-treated group and the blank control group.
Dextromethorphan metabolism was inhibited in the Flos
carthami-treated group compared to the control group in
a dose-dependent manner. The IC50 value of Flos carthami
was determined based on the concentration-inhibition curve
(Figure 4) and was used to represent the inhibitory eﬀect.
The IC50 value was 10.64mg/mL.
3.3. Comparison of Inhibitory Activities of Flos carthami
with Cimetidine. Our results showed that the dextromethor-
phan metabolic rate of the Flos carthami-treated group
(30mg/mL) was similar to that of the cimetidine-treated
group (0.6mg/mL). This result suggested that Flos carthami
could inhibit CYP2D6 activity (Figure 5).Evidence-Based Complementary and Alternative Medicine 5
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Figure 9: CYP2D6-mediated herb-drug interaction between Flos carthami and metoprolol or other CYP2D6 substrates.6 Evidence-Based Complementary and Alternative Medicine
3.4.EﬀectsofFloscarthamionPharmacokineticsofMetoprolol.
The chromatography of metoprolol and bisoprolol (internal
standard) in blood plasma was shown in Figure 6.T h e
mean metoprolol plasma concentration-time proﬁles were
overlaid by the blank control group (without Flos carthami
treatment) and the Flos carthami-treated group (Figure 7).
The metoprolol mean plasma PK parameters were shown in
Figure 8.
4. Discussion
The present study addresses the fact that CYP2D6 is involved
in the metabolism of Flos carthami in rats. One of the main
ﬁndings of the study is that the rate of dextromethorphan
metabolism in the Flos carthami-injected group is lower
than that of the blank control both in vivo and in vitro.
Dextromethorphan is widely used as a probe for CYP2D6
phenotypingandfortheassessmentofCYP2D6activity[18].
AllthedatahaveimpliedthatFloscarthamiinhibitsCYP2D6.
For further investigation on the eﬀect of Flos carthami
on CYP2D6, inhibition curve experiments were performed
using rat liver microsomes treated with the drug. The
metabolism of dextromethorphan was inhibited in the rat
liver microsomal reconstituted system treated with Flos
carthami, in a dose-dependent manner. One of the most
important ﬁndings of the current study is that Flos carthami
inhibits the activity of CYP2D6.
Cimetidine is a speciﬁc CYP2D6 inhibitor [19]; hence,
it was chosen to compare the inhibitory activities with Flos
carthami, and the result showed that the dextromethorphan
metabolic rate of 30mg/mL Flos carthami was similar to
that of 0.6mg/mL cimetidine in the rat liver microsomal
reconstituted system.
Flos carthami (also called saﬄower) is a traditional
Chinese herbal medicine and has extensive eﬀects on
the cardiovascular system, such as improving the micro-
circulation, anticoagulant, antihypertensive, antihyperlipi-
demia, antithrombotic, and hypoxia tolerance [20–23]. It is
applicable in treatment of coronary heart disease, angina,
myocardial infarction, hypertensive, atherosclerosis, cerebral
thrombosis, and so forth [24]. Clinically, Flos carthami
I n j e c t i o ni sv e r yc o m m o nt ob eu s e dc o n c o m i t a n t l yw i t h
otherWesterndrugsandmaybeusedincombinationwithβ-
blockers,suchasmetoprolol,totreatthecerebrovascularand
coronary heart diseases in China [25]. Because metoprolol
is a well-known CYP2D6 substrate, one has to consider the
possibleherb-druginteraction.Inthispaper,theeﬀectofFlos
carthami on metoprolol pharmacokinetics is investigated in
rats. Our data show that Flos carthami slowed down the
metabolic rate of metoprolol as suggested by prolonged
t1/2 (67.45%), by increased Cmax (74.51%) and AUC0–∞
(76.89%), in the Flos carthami-treated group as compared
to the blank control. These results suggest that CYP2D6 is a
riskfactorwhenFlos carthami is administered concomitantly
with metoprolol or other CYP2D6 substrates (Figure 9). The
current study provides strong evidence that the inhibition
of CYP2D6 by Flos carthami could result in elevated plasma
concentration of coadministered drugs that are substrates of
CYP2D6, which may cause adverse side eﬀects due to the
concentration of concomitantly used drugs over the limit of
the toxicity threshold, especially for the drugs with narrow
therapeutic windows.
CYP2D6 shows genetic polymorphism, and based on the
CYP2D6 activity, human beings are categorized as ultrarapid
metabolizers, extensive metabolizers, intermediate metabo-
lizers, and poor metabolizers [26, 27]. CYP2D6 is clinically
important in the metabolism of up to 25% of all clinical
drugs, including β-blockers, antiarrhythmics, antianginals,
antihypertensives, tricyclic antidepressants, neuroleptics,
neurotoxins, and endogenous neurochemicals [11, 28, 29].
The inhibitory eﬀect of Flos carthami on CYP2D6 activity
could be associated with polymorphism feature of CYP2D6,
which is clinically relevant when Flos carthami is admin-
istered with the drugs mentioned above or in individually
tailored drug doses.
Besides its clinical application, Flos carthami has also
been used as dietary supplements [23]. Therefore, it is
important to note that Flos carthami from food sources may
also alter the pharmacokinetics of other CYP2D6 substrates.
Several studies with regard to the eﬀects of Kampo
medications and botanical supplements on the CYP2D6
activity have been reported [30–32]. However, to the best of
our knowledge, this is the ﬁrst paper on a CYP2D6-mediated
interaction between Flos carthami and Western drugs in vivo.
Further investigation for the clinical signiﬁcance is needed.
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